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1. Glioblastoma and Clinical 
Translation
The clinical outcomes and 5-year survival 
rate for patients with glioblastoma (GB) 
make it among the most pernicious and 
challenging diseases to treat. Despite all 
the resources, time, and talent focused 
on developing targeted and/or local 
delivery technologies by the biomaterials 
community for GB, the clinical perfor-
mance of the FDA-approved therapy car-
mustine ((BCNU)-loaded polyanhydride 
wafers) and clinical trials of other mate-
rial approaches have been discouraging. 
As disappointing is the remarkably stag-
nant clinical translation of next- generation 
material approaches for GB. Despite 
encouraging preclinical results from 
hydrogels and modified wafer formula-
tions loaded with more efficacious chemo-
therapies, a total of zero have completed 
even a phase I clinical trial. Other strate-
gies, including convection-enhanced delivery, microsphere 
formulations, or drug-loaded nanoparticles have seen limited, 
albeit some, translation into the clinic with mixed results. This 
lackluster progress can be attributed, in part, to the paucity of 
communication between material scientists, biomedical scien-
tists, and clinicians. When examining the purported clinical 
relevance of embedding certain material properties into for-
mulations, it is clear that some widely known truths about the 
nature of GB progression among clinicians have not reached 
the biomaterials community.
Furthermore, a closer examination of the lessons from the 
BCNU wafers and other clinical trials of GB drug delivery 
materials may enrich and inspire materials scientists to create 
new systems that satisfy unmet medical needs identified by 
the clinical community. In tandem, clinicians and biomedical 
scientists may benefit from a short review highlighting the bio-
compatibility, safety, longevity, kinetics, tunability, and efficacy 
of promising new drug delivery materials without inundation 
by chemical and physical characterizations or discussions.
Another key challenge in treating GB is an incomplete 
understanding of disease pathophysiology, such as mecha-
nisms driving intrinsic and adaptive GB cell chemoresistance. 
A combined approach where biomedical scientists and material 
To date, the clinical outcomes and survival rates for patients with glioblas-
toma (GB) remain poor. A promising approach to disease-modification 
involves local delivery of adjuvant chemotherapy into the resection cavity, 
thus circumventing the restrictions imposed by the blood–brain barrier. The 
clinical performance of the only FDA-approved local therapy for GB [carmus-
tine (BCNU)-loaded polyanhydride wafers], however, has been disappointing. 
There is an unmet medical need in the local treatment of GB for drug delivery 
vehicles that provide sustained local release of small molecules and combina-
tion drugs over several months. Herein, key quantitative lessons from the use 
of local and systemic adjuvant chemotherapy for GB in the clinic are outlined, 
and it is discussed how these can inform the development of next-generation 
therapies. Several recent approaches are highlighted, and it is proposed that 
long-lasting soft materials can capture the value of stiff BCNU-loaded wafers 
while addressing a number of unmet medical needs. Finally, it is suggested 
that improved communication between materials scientists, biomedical 
scientists, and clinicians may facilitate translation of these materials into the 
clinic and ultimately lead to improved clinical outcomes.
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scientists work in parallel and in close communication with 
clini cians will be key for the timely development of optimal 
therapeutic options.
2. Principles of Cancer Treatment
Following a landmark phase III trial in 2005, the Stupp pro-
tocol was adopted as the standard of care for newly diagnosed 
GB: maximal safe surgical excision of the tumor mass, fol-
lowed by radiotherapy and concomitant temozolamide (TMZ), 
followed by adjuvant TMZ.[1] Despite the added ≈2.5 months 
survival afforded by the addition of TMZ, the 5-year survival 
rate[2] remains poor at 5%. A number of factors make GB dif-
ficult to treat: 1) the high proliferative and infiltrative capacity, 
heterogeneity, and intrinsic and acquired chemoresistance of 
neoplastic cells; 2) the tumor microenvironment; for example, 
the ability to induce anergic states in surrounding lymphocytes 
and glial cells, restricting the antitumor immune response; 
and 3) the brain macroenvironment; namely the surrounding 
blood–brain barrier and blood–tumor barrier restrict the ability 
of drugs to reach the brain parenchyma.[3] Despite these unique 
challenges, the goal of adjuvant oncological therapy (whether 
local or systemic) remains constant: maximizing cytotoxicity 
and reducing the risk of recurrence, while minimizing associ-
ated toxicity and the emergence of resistance. Indeed, the FDA-
approved BCNU wafer technology was developed with these 
needs in mind. By delivering chemotherapy directly into the 
tumor cavity, the restrictions imposed by the blood–brain bar-
rier are circumvented, and higher local drug concentrations can 
be achieved with limited systemic toxicity. However, drawing on 
general pharmacodynamics principles, are BCNU wafers opti-
mally designed to meet these targets?
Based on in vitro colony-forming inhibition studies, the cyto-
toxic actions of antitumor agents are, somewhat imprecisely, 
classified as time-dependent (cell cycle phase-specific agents) or 
concentration-dependent (cell cycle nonphase-specific agents).[4] 
This categorization has proved useful when designing clinical 
dosing regimens for systemically administered agents. In 
the case of TMZ, peak concentration, rather than prolonged 
exposure is thought to be more important for treatment effi-
cacy, consistent with its cell cycle nonphase-specific mode of 
action.[5,6] Accordingly, a dose-dense TMZ schedule (days 1 
through 21 of a 28-day cycle) does not improve survival in 
patients with newly diagnosed GB, compared to standard 
adjuvant treatment (days 1 through 5 of a 28-day cycle).[6] This 
logic should hold for BCNU wafers. Given the cell cycle non-
phase-specific (and therefore concentration-dependent) mode 
of action of BCNU, maximal antitumor effect should depend 
on peak cytotoxic drug level rather than duration of exposure. 
Accordingly, the FDA-approved wafers achieve high initial dose-
delivery of BCNU, which rapidly declines after 5–7 days.[7–10] 
Critically, however, systemic TMZ is administered repeatedly, as 
six 5-day 4-week cycles, and not as a single 5-day cycle (effec-
tively equivalent to the BCNU wafers). Indeed, increasing the 
number of adjuvant TMZ cycles from 6 to 12 improves overall 
survival by 8.4 months.[11] This therapeutic benefit may be 
mediated by both increased cytotoxicity, triggered by increased 
TMZ-mediated DNA alkylation, and minimization of acquired 
resistance driven by suboptimal drug exposure.[12] This key 
lesson has been lost with the shift in focus from systemic to 
locally administered chemotherapy. The antitumor effect of any 
chemotherapeutic agent, regardless of route of administration, 
is time-critical: contingent on duration of exposure for time-
dependent agents, and repeated high-dose exposure over time 
for concentration-dependent agents.
Optimizing chemotherapy dosing regimens also depends 
on the trade-off between increasing drug dose/exposure to 
enhance antitumor activity and minimizing concomitant tox-
icity. The extended 12-cycle TMZ regimen may improve sur-
vival relative to 6 cycles, but at the expense of increased hema-
tological toxicity.[11] Indeed, the minimum survival threshold 
at which patients accept chemotherapy closely relates to the 
severity of its toxic side effects.[13] Reasonably, this principle 
was not prioritized in the development of the BCNU wafers, 
given that local delivery of BCNU circumvents the problem 
of high toxicity associated with systemic administration.[14,15] 
BCNU wafers seem to be associated with a number of local 
adverse events (namely cerebral oedema, intracranial infec-
tion, and pericavity necrosis), more than those expected 
from resection alone.[16–19] Side effects peak in the weeks/
months following implantation, and can persists for up to 
6 months.[17,19,20] Interestingly, this more closely corresponds 
to the time-scale of polymer degradation than the release 
kinetics of BCNU, suggesting that these side effects are more 
closely related to persistence of the wafer within the resection 
cavity than to early BCNU release.[7–10] In light of this, it is per-
haps unsurprising that phase III trials comparing BCNU to 
placebo wafer have reported similar rates of adverse effects.[21] 
After FDA-approval of the BCNU wafers, and with treatment 
extended to patients who were not eligible in the initial clinical 
trials, mounting concerns were reported through case reports/
series, and these may more closely reflect the comparison of 
wafer to standard resection.[22]
Two chemotherapeutic principles, the importance of sus-
tained/frequent drug exposure and the efficacy versus toxicity 
trade-off, were perhaps too readily dismissed in the move from 
systemic to local chemotherapy delivery. Immediately postim-
plant, BCNU is rapidly released from the wafer, in a “1-cycle” 
fashion: the wafer delivers the majority of its chemo-payload 
in under 1 week.[9,10,22] This explains, in part, why the effi-
cacy of BCNU wafers has been modest at best. Subsequently, 
the empty wafer persists in the resection cavity, heightening 
adverse effects without concomitant clinical benefit.
Notably, while cyclic dosing may translate into clinical dividends 
in some patients, lack of a widely efficacious chemotherapeutic 
agent remains an issue. Namely, patients with unmethylated 
O6-Methylguanine-DNA-methyltransferase (MGMT) promoter 
GMs respond poorly to treatment with DNA alkylating agents 
such as TMZ[23] and BCNU[24]; among patients with methylated 
MGMT promoter GMs, the addition of TMZ to radiotherapy 
confers significant survival benefit (≈6.4 months) which is 
minimal (≈0.9 months) among patients lacking methylation of the 
MGMT promoter.[23] Once-susceptible GM cells can also acquire 
resistance to TMZ following repeated exposure to the drug via 
mechanisms including upregulation of MGMT levels and down-
regulation of DNA mismatch-repair proteins.[25] Overcoming this 
challenge will require that materials science research advances in 
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tandem and in close collaboration with drug discovery, which is 
informed by biomedical scientists and their mechanistic insights 
into GM pathophysiology.
3. Outcomes and Lessons from the Clinic
While the clinical benefits of BCNU wafers have not greatly 
ameliorated the tumor burden in GB patients,[26] an abun-
dance of clinical literature using this adjuvant therapy  provides 
key and quantitative lessons for the next generation of local 
chemotherapy delivery systems. In the development of the 
underlying material of the wafer technology, a motivational 
principle was the sustained local delivery of a high chemo-
therapy concentration within the pharmaceutical window as an 
adjuvant therapy.[27–30] The distinct time scales of drug release 
and material longevity in vivo are among the most critical fac-
tors involved in developing, optimizing, and evaluating drug 
delivery technology and have not been given the attention they 
deserve. Furthermore, a key lesson from the clinic is that the 
increase to an extended 12-cycle TMZ regimen may provide 
benefit in reducing tumor burden and prolonging survival (See 
Figure 1).
3.1. Key Lessons
a) Increasing the number of adjuvant systemic TMZ cycles con-
fers a survival benefit, at the cost of heightened side effects.
b) BCNU wafers release the majority of drug payload in the first 
week, and the side effects of this technology begin after this 
massive initial bolus release.
c) A higher stiffness matrix does not automatically equate to 
prolonged release in vivo, and importantly the higher stiff-
ness may exacerbate the negative side effects.
3.2. Critical Materials Challenges and Unmet Medical Needs
a) Local delivery whose time scale for drug release is on par with 
the time scale for matrix degradation.
b) Materials capable of eluting a prolonged 0th or 1st order 
 release of drug on time scales of months rather than days.
c) Achieving such pharmacokinetic properties with a degrada-
ble, soft material.
In summary, BCNU wafers are too stiff [31,32] and remain 
too long in the body for the therapeutic benefit they provide. 
Novel methods for local chemotherapy emerging from the 
biomaterials community should be considered. We hypoth-
esize that improved efficacy and reduced toxicity may depend 
on, at minimum, providing the same bolus release of chemo-
therapy from a softer material that biodegrades much faster 
than the wafer technology. Further benefit, albeit a more tech-
nologically challenging solution, may be realized by devel-
oping a degradable soft material that remains in the body 
on the order of 6–12 months while simultaneously eluting 
chemotherapy with 0th or 1st order release kinetics for the 
same duration.
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Figure 1. Graphical illustration of concentration, efficacy, and toxicity 
profiles of an idealized drug delivery system against systemic TMZ 
adjuvant therapy (Stupp protocol) and stiff FDA-approved BCNU wafers. 
a) Limitations in systemic toxicity of TMZ are overcome with local 
delivery. An ideal delivery system will possess a mitigated bolus and 0th 
or 1st order release kinetics. b) Achievement of a high local concentration 
of TMZ in local delivery systems sustained over many weeks produces a 
reduction in tumor burden and increase in efficacy in the idealized local 
delivery systems. c) BCNU wafers’ stiffness mismatch with tissue con-
tribute to toxicity and negative side effects after >80% of drug release. 
A soft idealized local drug delivery system will have minimal acute toxicity 
and no negative chronic immune response.
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4. Promising Soft Materials for Local Delivery
There is mounting evidence from the biomaterials community 
that existing hydrogel technology can capture the value of a 
wafer-type local therapy while mitigating negative side effects, 
putting them at the forefront of promising local chemotherapy 
delivery systems in GB. Recent reviews have summarized some 
of the literature on these local drug delivery hydrogels.[32,33] 
Certain systems are particularly promising, or have developed 
proof-of-concept principles that should be adopted with any 
clinical therapy.
Degradable, soft hydrogels, which are distinct from classic 
nondegradable materials such as polyHEMA hydrogels, have 
a number of advantages compared to BCNU wafers. As dis-
cussed, wafers elute the vast majority of their chemotherapy 
payload in 1 week, but the remaining empty wafer may 
increase the risk of local adverse effects. Critically, hydrogels 
can be tuned to degrade under different time-scales and are 
generally biodegraded in under 1 month. Although the kinetics 
of chemotherapy release may be comparable, hydrogels do not 
last long enough in the resection cavity (nor are stiff enough) 
to cause the same adverse effects as wafers. Promising exam-
ples of rapidly biodegradable hydrogels include supramolecular 
or physically assembled hydrogels for parenteral drug delivery 
applications.[32,34–36] For example, we previously reported 
physical hydrogels for local GB drug delivery that self-assemble 
via host–guest interactions.[31,37] These materials release drugs 
with a bolus, just as the BCNU wafers do, but are biodegrad-
able under timescales of days to weeks. These materials confer 
an additional advantage over wafers: because their intended 
use is in less-invasive parenteral drug delivery, materials sci-
entists often embed shear-thinning properties into these 
supramolecular hydrogels so that they can be nonsurgically 
implanted in vivo and quickly recover their original stiffness. 
Stiff BCNU wafers do not possess these shear-thinning and 
recovery properties. This injectability is advantageous for GB 
drug delivery because as the material recovers, it fills the gap 
of the resected tumor with superior epitaxial engagement.[31,32] 
Preclinical data suggest this improvement in bioavailability 
affords clear therapeutic benefit,[31] which may mean that 
shear-thinning soft materials, while retaining the bolus release 
kinetics of the wafer technology, are more efficacious than their 
stiff counterparts.
However, if local drug delivery for GB is to move away from 
this wafer paradigm of 1-cycle benefit, and adopt the more ben-
eficial pharmacokinetic profile from systemic therapy, which 
includes repeated cycles of TMZ over the course of several 
months, then the local drug delivery material cannot degrade 
in under 1 month, as is the case with degradable, physical 
hydrogels. Furthermore, the local therapy cannot elute most of 
its payload in under 1 month, as is the case with both physical 
hydrogels and the BCNU wafers. To avoid the side effects of the 
wafer, the local drug delivery adjuvant should also be soft with 
a stiffness on par with that of tissue. This is no easy task: it is 
highly challenging to develop a physical hydrogel which is bio-
compatible, biodegradable, injectable, soft, and has an in vivo 
duration greater than 1 month. This particularly burdensome 
engineering challenge will require new and creative solutions 
in chemistry and materials science.
Of course, developing long-lasting, soft, and degradable 
materials for GB delivery is only useful if the timescale of 
drug elution is also on the order of 6–12 months. As previ-
ously discussed, most supramolecular hydrogels and the 
FDA-approved wafers possess a bolus release profile. Many 
approaches have been reported in the literature to mitigate 
a bolus release, including using capsules or nanoparticles 
to retard the drug release by introducing an upstream rate-
limiting step.[38–40] Ranganath et al. demonstrated the utility 
of poly(lactic-co-glycolic acid) (PLGA) nanocarriers in pro-
viding sustained drug release and greater engineering control 
over the release kinetics for a GB target.[38,39] Rahman et al. 
explored the utility of an interesting PLGA/PEG microparticle-
based paste as a local adjuvant therapy.[41] Such an approach 
is potentially advantageous in particular for selective tuning of 
release kinetics for combination therapies, i.e., changing the 
release rate of one drug (e.g., hydrophobic small molecule) 
without disturbing the release rate of a second loaded drug 
(e.g., protein).
Other approaches include exploiting lipid carriers.[42–45] 
These strategies are promising in providing a scalable method 
of reducing a bolus release of drugs; in particular, their utility 
in controlling the release kinetics and improving stability of 
hydrophobic small molecule drugs[46] is especially useful in 
anticancer therapy. The delivery of hydrophobic drugs is an 
important[47] and active area of research, and such lipid carriers 
are promising both for delivery of these poorly soluble drugs 
and combination therapies with proteins.
The field has begun to turn to hydrophobic moieties not just 
for controlled elution of a therapeutically relevant concentration 
of hydrophobic small molecules, but as a means of overcoming 
the fundamental mass transfer limitations in controlled drug 
delivery using a water-based material. Soft materials that 
serve as alternatives to supramolecular hydrogels include sys-
tems such as oleogels.[48] These nonaqueous gels have seen 
virtually no translation into GB local therapeutics, but a new 
generation of solvent-free, soft biomaterials for drug delivery 
are emerging, including supramolecular poly(caprolactone)/
poly(ethylene glycol) block polymer systems[36] developed by 
Tabet and Wang. Hydrophobic solvent-free gels are promising 
because the absence of bulk  solvent may prolong their release 
kinetics in vivo.
5. Conclusions
In summary, results from the clinic provide useful quantitative 
lessons and benchmarks to guide the biomaterials community 
in developing novel local chemotherapy delivery systems. The 
clinical success of a higher number of adjuvant systemic TMZ 
cycles should guide the adoption of similar time scales and 
release kinetics in local drug delivery materials. The stiffness 
mismatch of BCNU wafers informs the mechanical properties 
that ideal systems will have.
Many promising soft materials for local drug delivery are in 
development but have seen little clinical translation. It would 
be advantageous for physicians to explore such systems utility 
as adjuvant therapies. These materials are immediately avail-
able and have strong potential to both mitigate negative side 
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effects incurred from BCNU wafers and provide a more effica-
cious bolus release due to superior epitaxial engagement.
Unmet medical needs remain, and biodegradable soft mate-
rials that have extended durations in vivo and elute chemo-
therapy for similar time scales of many months may very 
 elegantly satisfy these needs. Transdisciplinary communication 
between clinicians, material scientists, and biomedical scien-
tists is needed for the clinical translation of novel therapies that 
satisfy such engineering requirements.
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